Skip to main content

Table 6 Outcomes across the EGDT, ProCESS, and ARISE trials

From: Early goal-directed therapy in severe sepsis and septic shock: insights and comparisons to ProCESS, ProMISe, and ARISE

  EGDT ProCESS ARISE ProMISe
  EGDT Control EGDT PBST UC EGDT UC EGDT UC
APACHE II at enrollment 21.4 ± 6.9 20.4 ± 7.4 20.8 ± 8.1 20.6 ± 7.4 20.7 ± 7.5 15.4 15.8 18.7 ± 7.1 18.0 ± 7.1
Predicted mortality, % based on APACHE II 40.3 36.9 38.2 37.5 37.9 21.0 21.0 30.2 29.1
In-hospital mortality, % (actual) 30.5 46.5 21.0 18.2 18.9 14.5 15.7 25.6 24.6
Predicted minus actual mortality, % 9.8 −9.6 17.2 19.3 19.0 6.5 5.3 4.6 4.5
Relative risk reduction in hospital mortality 24.3 −26.0 45.0 51.5 50.1 30.9 25.2 25.6 24.6
Incidence of cardiovascular complications % 10 20 5.2 4.9 8.1 7.1 5.3 2.1 1.6
  1. APACHE II Acute Physiology and Chronic Health Evaluation II, ARISE Australasian Resuscitation in Sepsis Evaluation, EGDT Early Goal-Directed Therapy, PBST protocol-based standard therapy, ProCESS Protocolized Care for Early Septic Shock, ProMISe Protocolized Management of Sepsis, UC usual care